Wire · opportunities
How a 63-Patient Trial Delivered an FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
The FDA approved Pasatru (garetosmab-grts), a monoclonal antibody therapy to reduce new bone lesions and flare-ups in fibrodysplasia ossificans progressiva, based on a 63-patient phase 3 trial using CT-scan efficacy endpoints. This is the first FDA-approved treatment for this ultra-rare genetic disorder and highlights the potential for small trials with imaging-based endpoints in orphan disease drug development.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 19 Aug 2026 and 20 Aug 2026.
◆ ◆ The Wire takeaway
FDA's approval based on a small 63-patient trial signals that founders developing treatments for ultra-rare diseases can pursue accelerated paths leveraging advanced imaging for efficacy. You should now evaluate streamlined trial designs using quantitative endpoints to speed market entry and address small populations.
◆ Coverage
4 sources · first reported 19 Aug 2026 · latest 20 Aug 2026
◆ Related on Wire
◆ Topics